HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? (Q38174260)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Mauro Viganò

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Giampaolo Mangia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

34 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

120-126

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373088%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

3 March 2020

cites work

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Antiviral drugs for HBV liver disease.

21 January 2018

1 reference

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

21 January 2018

1 reference

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

21 January 2018

1 reference

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

21 January 2018

1 reference

Results of treatment of chronic hepatitis B with pegylated interferon.

21 January 2018

1 reference

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901.

21 January 2018

1 reference

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

21 January 2018

1 reference

Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence

21 January 2018

1 reference

Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal

21 January 2018

1 reference

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.

21 January 2018

1 reference

The role of HBsAg quantification for monitoring natural history and treatment outcome

21 January 2018

1 reference

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

21 January 2018

1 reference

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

21 January 2018

1 reference

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

21 January 2018

1 reference

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

21 January 2018

1 reference